Fifth Third Bancorp Grows Holdings in Moderna, Inc. $MRNA

Fifth Third Bancorp grew its position in shares of Moderna, Inc. (NASDAQ:MRNA) by 52.9% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 32,088 shares of the company’s stock after purchasing an additional 11,108 shares during the period. Fifth Third Bancorp’s holdings in Moderna were worth $829,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of MRNA. Rothschild Investment LLC lifted its stake in shares of Moderna by 94.1% during the second quarter. Rothschild Investment LLC now owns 920 shares of the company’s stock valued at $25,000 after buying an additional 446 shares during the period. Atlantic Union Bankshares Corp acquired a new position in Moderna in the 2nd quarter valued at $26,000. Whittier Trust Co. purchased a new position in shares of Moderna during the 2nd quarter worth $28,000. MUFG Securities EMEA plc acquired a new stake in shares of Moderna during the second quarter worth $28,000. Finally, Assetmark Inc. grew its position in shares of Moderna by 137.7% in the second quarter. Assetmark Inc. now owns 1,298 shares of the company’s stock valued at $36,000 after purchasing an additional 752 shares during the period. Institutional investors and hedge funds own 75.33% of the company’s stock.

More Moderna News

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: FDA will review Moderna’s mRNA flu vaccine application after an initial refusal-to-file, with regulators now targeting a decision by Aug. 5, 2026 — a reversal that boosts the commercial outlook for a new recurring vaccine market and spurred an earlier jump in the stock. Moderna Stock Jumps After FDA Reverses Course on Flu Shot
• Positive Sentiment: Goldman Sachs analyst flagged upside for MRNA, an institutional vote of confidence that can support sentiment and buying interest. Moderna (NASDAQ:MRNA) Stock Price Expected to Rise, The Goldman Sachs Group Analyst Says
• Neutral Sentiment: Moderna will present at TD Cowen and Barclays healthcare conferences in March — routine investor access that may provide more management detail but is unlikely by itself to move the stock dramatically. Moderna to Present at Upcoming Conferences in March 2026
• Negative Sentiment: BioNTech sued Moderna in Delaware federal court alleging Moderna’s mNexspike infringes a patent tied to BioNTech/Pfizer’s Comirnaty—new litigation increases legal risk, potential damages or injunctions, and heightens competitive/legal uncertainty for Moderna’s COVID-19/respiratory vaccine portfolio. BioNTech sues Moderna for patent infringement over COVID-19 shots
• Negative Sentiment: A court recently rejected two of Moderna’s defenses in its patent dispute with Arbutus, representing another legal setback that could increase exposure and costs from long-running mRNA technology litigation. Court Rejects Two Moderna Defenses in mRNA Vaccine Patent Row With Arbutus

Analyst Ratings Changes

Several equities analysts recently weighed in on MRNA shares. Wolfe Research reiterated an “underperform” rating and set a $17.00 target price on shares of Moderna in a research report on Thursday, November 20th. UBS Group reaffirmed a “neutral” rating and set a $36.00 price objective on shares of Moderna in a research note on Monday. Leerink Partners reiterated an “underperform” rating on shares of Moderna in a report on Friday, January 30th. Piper Sandler restated an “overweight” rating on shares of Moderna in a report on Monday, December 1st. Finally, Berenberg Bank set a $28.00 price target on shares of Moderna in a research report on Monday, November 17th. Two research analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and five have given a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Reduce” and an average target price of $31.47.

Insider Activity at Moderna

In related news, Director Noubar Afeyan sold 23,853 shares of Moderna stock in a transaction on Thursday, December 11th. The shares were sold at an average price of $29.48, for a total transaction of $703,186.44. Following the transaction, the director owned 3,924 shares in the company, valued at approximately $115,679.52. The trade was a 85.87% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 10.90% of the company’s stock.

Moderna Stock Performance

NASDAQ MRNA opened at $49.87 on Friday. The company has a debt-to-equity ratio of 0.07, a current ratio of 3.29 and a quick ratio of 3.22. Moderna, Inc. has a 1-year low of $22.28 and a 1-year high of $55.20. The firm has a market capitalization of $19.49 billion, a P/E ratio of -6.86 and a beta of 1.32. The business’s 50-day simple moving average is $39.02 and its 200-day simple moving average is $30.44.

Moderna (NASDAQ:MRNA) last posted its quarterly earnings results on Friday, February 13th. The company reported ($2.11) EPS for the quarter, beating the consensus estimate of ($2.79) by $0.68. The firm had revenue of $678.00 million for the quarter, compared to analyst estimates of $611.14 million. Moderna had a negative net margin of 145.16% and a negative return on equity of 30.15%. Moderna’s revenue for the quarter was down 33.2% compared to the same quarter last year. During the same quarter last year, the firm posted ($2.91) earnings per share. Equities analysts predict that Moderna, Inc. will post -9.61 EPS for the current year.

Moderna Company Profile

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.